» Articles » PMID: 37146937

CircRNAs in Tumor Immunity and Immunotherapy: Perspectives from Innate and Adaptive Immunity

Overview
Journal Cancer Lett
Specialty Oncology
Date 2023 May 5
PMID 37146937
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor immunotherapy is a new therapeutic approach that has been evolving in the last decade and has dramatically changed the treatment options for cancer. Circular RNAs (circRNAs) are non-coding RNAs (ncRNAs) with high stability, tissue-specific and cell-specific expression. There is growing evidence that circRNAs are involved in the regulation of both adaptive and innate immunity. They play important roles in tumor immunotherapy by affecting macrophage, NK and T cell function. The high stability and tissue specificity make them ideal candidate biomarkers for therapeutic effects. CircRNAs also represent one of promising targets or adjuvant for immunotherapy. Investigations in this field progress rapidly and provide essential support for the diagnosis, prognosis and treatment guidance of cancers in the future. In this review, we summarize the role of circRNAs on tumor immunity from the viewpoint of innate and adaptive immunity, and explore the role of circRNAs in tumor immunotherapy.

Citing Articles

Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways.

Zhang Y, Guo N, Zhu H, Liu M, Hao J, Wang S Theranostics. 2024; 14(18):7054-7071.

PMID: 39629133 PMC: 11610140. DOI: 10.7150/thno.102037.


The multifaceted roles of circular RNAs in cancer hallmarks: From mechanisms to clinical implications.

Kundu I, Varshney S, Karnati S, Naidu S Mol Ther Nucleic Acids. 2024; 35(3):102286.

PMID: 39188305 PMC: 11345389. DOI: 10.1016/j.omtn.2024.102286.


circRNAs in Endometrial Cancer-A Promising Biomarker: State of the Art.

Wlodarczyk K, Kurylo W, Pawlowska-Lachut A, Skiba W, Suszczyk D, Pieniadz P Int J Mol Sci. 2024; 25(12).

PMID: 38928094 PMC: 11203539. DOI: 10.3390/ijms25126387.


N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair.

Jiang S, Gao L, Li J, Zhang F, Zhang Y, Liu J Front Cell Dev Biol. 2024; 12:1383232.

PMID: 38586304 PMC: 10995360. DOI: 10.3389/fcell.2024.1383232.


Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.

Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H Mol Cancer. 2024; 23(1):20.

PMID: 38254110 PMC: 10802008. DOI: 10.1186/s12943-023-01928-2.